# Protembis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protembis

- Industry: Medical Devices & Equipment
- Headquarters: Aachen, Germany
- Website: www.protembis.com/
- Total disclosed funding: $42M
- Latest round: Series B (Mar 29, 2024)
- Investors on record: 13

## About

Protembis GmbH, based in Aachen, Germany, specializes in innovative medical technologies that enhance safety during cardiology procedures, particularly transcatheter aortic valve replacement.Protembis GmbH develops advanced medical solutions focused on brain protection during cardiology interventions. Founded in 2013, the company has successfully completed multiple funding rounds, with the latest being a Series B round raising EUR 30.000 mn, led by notable investors including 5FP GbR and ARVE Capital. Conrad Rasmus, the founder, has a background in medical technology innovation. The company has raised a total of EUR 30.000 mn to date, with a current valuation of EUR 186.160 mn. The most recent deal occurred on July 26, 2024, contributing to their ongoing growth efforts.Protembis GmbH specializes in the development of innovative medical technologies aimed at reducing the risk of brain injuries during cardiology procedures, particularly those involving transcatheter aortic valve replacement (TAVR). Their flagship product, the ProtEmbo® Cerebral Protection System (CPS), is engineered to ensure comprehensive brain protection during TAVR procedures, effectively mitigating the occurrence of silent brain infarcts that can lead to covert clinical strokes and potential long-term cognitive decline. Clinical studies have demonstrated the efficacy and safety of the ProtEmbo system, with many patients showing no clinically meaningful brain lesions post-procedure. The company's primary clientele includes healthcare providers and hospitals across Europe and North America, focusing on markets where TAVR is a standard treatment for aortic stenosis.Protembis operates a B2B model, engaging directly with hospitals and healthcare institutions that perform TAVR procedures. Revenue is generated through the sale of the ProtEmbo system, which is utilized during these interventions to improve patient outcomes by minimizing the risk of cerebral complications. The company explores partnerships and collaborations with medical device distributors and healthcare organizations to broaden its market reach. Revenue generation primarily relies on unit sales of the ProtEmbo system, alongside potential service agreements related to training and support for the implementation of this technology in clinical environments, ensuring integration into existing medical practices for cardiologists and patients undergoing TAVR.Protembis GmbH plans to leverage the EUR 20 million raised in venture debt funding from the European Investment Bank in July 2024 to complete clinical trials and enhance marketing efforts for the ProtEmbo system. The company is actively developing new products designed to improve patient safety during cardiac procedures and aims to expand into additional markets across Europe and North America by 2025.

## Funding rounds

- Series B, Mar 29, 2024, $32M — Coparion, roellpartners, Abiomed, Inc., TechVision Fonds, BPO Capital, Scope Hanson, Segulah Medical Acceleration, Arve Capital, 5FP GbR, JOPO GmbH, Gehrenberg zweite Investment GmbH & Co. KG, XGEN Venture
- Series A, Sep 13, 2018, $10M — Seedfonds Aachen, Coparion, Abiomed, Inc.

## Investors

- Seedfonds Aachen — Series A
- Coparion (https://capitalatlas.ai/funds/coparion) — Series A, Series B
- Abiomed, Inc. — Series A, Series B
- roellpartners — Series B
- TechVision Fonds (https://capitalatlas.ai/funds/techvision-fonds) — Series B
- BPO Capital — Series B
- Scope Hanson (https://capitalatlas.ai/funds/scope-hanson) — Series B
- Segulah Medical Acceleration (https://capitalatlas.ai/funds/segulah-medical-acceleration) — Series B
- Arve Capital (https://capitalatlas.ai/funds/arve-capital) — Series B
- 5FP GbR — Series B
- JOPO GmbH — Series B
- Gehrenberg zweite Investment GmbH & Co. KG — Series B
- XGEN Venture (https://capitalatlas.ai/funds/xgen-venture) — Series B